New evidence on why young women in South Africa are at high risk of HIV infection

July 18, 2016

Evidence by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) consortium of South African and North American researchers will be presented on July 18 at the International AIDS 2016 Conference in Durban, shedding new light on why young women in South Africa have high rates of HIV infection. Dr. Salim Abdool-Karim, professor of Epidemiology at Columbia University's Mailman School of Public Health and director of CAPRISA, led the research team. The Mailman School was also among the North American institutions providing research support.

In a study of 9,812 individuals, the genetic code of HIV from each of 1,589 HIV-positive people was analyzed to better understand the relentless spread of HIV in a rural and urban community in South Africa. It revealed a "cycle of HIV transmission" driven by high rates of new HIV infections in adolescent girls and young women from men, on average 8 years older. Many of these men were also partners of similarly aged women who have HIV prevalence rates exceeding 60%.

In a second study investigating the genetic codes of vaginal bacteria of 120 South African women, those with an overgrowth of Prevotella bivia had an almost 20 times higher chance of acquiring HIV than those low levels or absence of this vaginal bacterium. Further, it was found that Prevotella bivia may be increasing women's vulnerability to HIV by inflammation in the vagina through its release of "lipopolysaccharide" (LPS), a well-known immuno-stimulatory molecule in HIV infection.

In the third study, an analysis of 3,334 genital bacterial proteins from 688 women showed that the three out of five women who had a "healthy" lactobacillus dominant vagina showed that tenofovir gel preexposure prophylaxis was effective in preventing HIV, while the women who did not have locatobacillus dominance, showed little benefit from the gel Follow up laboratory studies showed that Gardnerella vaginalis, which predominates in the vagina when lactobacillus levels are low, absorbs tenofovir thereby reducing the availability of the drug to prevent HIV infection.

"Reducing new HIV infections in young women is one of the greatest challenges in southern Africa," commented Dr. Abdool Karim. "Based on our results, implementing a combination of evidence-based targeted interventions to break the cycle of HIV transmission while effectively treating bacterial vaginosis could enhance HIV prevention in women in the highest HIV-burden region of the world."

The three studies provide scientific evidence, using state-of-the-art research technologies, to guide targeted HIV prevention interventions to break the cycle of HIV transmission and impact the course for HIV in South Africa and potentially in other high burden settings. Since the Prevotella and Gardnerella bacteria raise the vaginal pH, a readily available, quick, simple and cheap test can be used to ascertain which women require treatment for bacterial vaginosis, an imbalance in the vaginal bacteria. Combined, these interventions could have a significant impact on the spread of HIV in women in South Africa and beyond.

Dr Margaret Chan, Director-General, World Health Organization, commented that, "Young women in Africa have missed out while others have benefitted from global progress against AIDS. The new studies point the way to HIV prevention opportunities that can help rectify this imbalance."

"The new evidence from the UNAIDS Collaborating Centre - CAPRISA takes us closer to understanding the very of HIV among young women and adolescent girls in southern Africa" said Michel Sidibé, the Executive Director of UNAIDS. "We cannot leave women and girls behind in this Fast-Track response—in addition to scaling up the options we have, effective new tools are required urgently to meet their HIV prevention needs if we are to end this epidemic by 2030."

"Reducing new HIV infections in young women is one of PEPFAR's highest priorities", said Dr. Deborah Birx, United States Ambassador and Global AIDS Coordinator. "The CAPRISA findings provide us with a greater understanding of how to protect young women. This groundbreaking study suggests young women may have been very compliant with PrEP. This new insight will allow us to move forward with a different understanding of how best to protect women from HIV".

In most of southern and eastern Africa, HIV incidence in young women (less than 25 years) continues to remain unacceptably high. About 380 000 new HIV infections occur in and young women aged 16-24 years each year. These young women experience HIV rates several-fold higher than their male peers, making the reduction of infection rates among one of the most crucial challenges in HIV prevention in Africa.

Explore further: HIV/AIDS still top killer of African adolescents

Related Stories

HIV/AIDS still top killer of African adolescents

July 18, 2016
HIV/AIDS remains the leading cause of death among Africans aged between 10 and 19, UNICEF chief Anthony Lake said Monday at the start of a major international conference on the virus.

Sub-Saharan women using modern contraceptives more likely to be HIV tested

April 26, 2016
Women in sub-Saharan Africa who use modern contraceptives are more likely to be tested for HIV than those who do not, according to a study published April 25, 2016 in the open-access journal PLOS ONE by Katherine Center from ...

Male circumcision, HIV treatment can significantly reduce new infections in African men

July 12, 2016
Increasing the number of men who undergo circumcision and increasing the rates at which women with HIV are given antiretroviral therapy (ART) were associated with significant declines in the number of new male HIV infections ...

Quest to end AIDS epidemic at risk: UN

July 12, 2016
Efforts to end the global AIDS pandemic by 2030 are lagging, the UN warned Tuesday, decrying rising numbers of new HIV infections among adults in many regions, with Russia especially hard-hit.

Invasive prenatal testing doesn't up HIV transmission risk

July 1, 2016
(HealthDay)—For pregnant women with HIV infection, invasive prenatal testing does not increase the risk of vertical transmission, according to a study published online June 20 in BJOG: An International Journal of Obstetrics ...

Most women diagnosed with HIV in pregnancy retained in care

June 20, 2016
(HealthDay)—Most women diagnosed with HIV during pregnancy are still retained in clinical care over the first year postpartum, according to a study published in the July issue of Obstetrics & Gynecology.

Recommended for you

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

Research finds home-based kit would increase HIV testing

July 31, 2017
Research led by William Robinson, PhD, Associate Research Professor of Behavioral & Community Health Sciences at LSU Health New Orleans School of Public Health, has found that 86% of heterosexuals who are at high risk for ...

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.